No Data
No Data
Optimistic Outlook: Biote's Growth Potential and Strategic Initiatives Despite Transitional Challenges
Biote Corp. Releases March 2024 Investor Presentation
Express News | Biote Shares Are Trading Higher After the Company Reported Better-than-expected Q$ GAAP EPS Results
Biote Soars 22% With Expected Acceleration in 2H 2024 Sales
By Emon Reiser Shares of Biote were rising sharply after the hormone therapy company on Tuesday reaffirmed its financial guidance and said it expects growth to accelerate in the second half of the ye
Roth MKM Reiterates Buy on Biote, Raises Price Target to $9
Roth MKM analyst George Kelly reiterates Biote with a Buy and raises the price target from $8 to $9.
Biote Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/13/2024 39.97% Roth MKM $8 → $9 Reiterates Buy → Buy 02/20/2024 39.97% B. Riley Securities → $9 Initiat
No Data